The University of Chicago Header Logo

Walter M. Stadler

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
Phone+1 (773) 702-4400
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Stadler is a clinical trialist focused on developing novel therapies and biomarkers, especially for genitourinary cancer. In addition to an extensive history performing trials in kidney, bladder, and prostate cancer, he also has broad experience in leading efforts supporting clinical trial infrastructure and conduct. These include renal cancer cadre leader for the Cancer and Leukemia Group B (CALGB, now Alliance), PI for a DOD funded prostate cancer clinical trials consortium, co-PI for a Prostate Cancer SPORE, PI for the NCI funded N01 contract for early phase clinical trials, and a current role as Dean for Clinical Research

    Collapse Biography 
    Collapse education and training
    University of Illinois, Urbana, ILBS01/1984Chemistry
    Yale University School of Medicine, New Haven, CTMD06/1988Medicine
    Michael Reese Hospital, Chicago, ILResident06/1991Internal Medicine
    University of Chicago, Chicago, ILFellow01/1993Oncology
    University of Chicago, Chicago, ILPostdoctoral Fellow06/1994Oncology

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lynch C, Sweis RF, Modi P, Agarwal PK, Szmulewitz RZ, Stadler WM, O'Donnell PH, Liauw SL, Pitroda SP. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 Jan 09. PMID: 38228414.
      Citations:    Fields:    
    2. Strohbehn GW, Stadler WM, Boonstra PS, Ratain MJ. Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2023 Dec 27; 17407745231213882. PMID: 38148731.
      Citations:    Fields:    
    3. Paller CJ, Barata PC, Lorentz J, Appleman LJ, Armstrong AJ, DeMarco TA, Dreicer R, Elrod JAB, Fleming M, George C, Heath EI, Hussain MHA, Mao S, McKay RR, Morgans AK, Orton M, Pili R, Riedel E, Saraiya B, Sigmond J, Sokolova A, Stadler WM, Tran C, Macario N, Vinson J, Green R, Cheng HH, PROMISE Trial Investigators. PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. Prostate. 2024 Feb; 84(3):292-302. PMID: 37964482.
      Citations:    Fields:    Translation:Humans
    4. Meier JP, Zhang HJ, Freifelder R, Bhuiyan M, Selman P, Mendez M, Kankanamalage PHA, Brossard T, Pusateri A, Tsai HM, Leoni L, Penano S, Ghosh K, Broder BA, Markiewicz E, Renne A, Stadler W, Weichselbaum R, Nolen J, Kao CM, Chitneni SK, Rotsch DA, Szmulewitz RZ, Chen CT. Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics. Molecules. 2023 Aug 13; 28(16). PMID: 37630292; PMCID: PMC10458970.
      Citations: 1     Fields:    Translation:HumansAnimals
    5. Paydary K, DeLuca A, Aggarwal R, Wall L, Stadler WM. Enrollment Barriers for Molecular Targeted Trials. JAMA Oncol. 2023 Jun 01; 9(6):863-864. PMID: 37022722; PMCID: PMC10080401.
      Citations:    Fields:    Translation:Humans
    6. Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722. PMID: 37182801; PMCID: PMC10696593.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Figlin R, Powles T, Akella L, Orford K, Escudier B, Mellado B, Sepúlveda Sánchez JM. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418. PMID: 36048457; PMCID: PMC9437824.
      Citations: 13     Fields:    Translation:Humans
    8. VanderWeele DJ, Kocherginsky M, Munir S, Martone B, Sagar V, Morgans A, Stadler WM, Abdulkadir S, Hussain M. A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 Dec; 20(6):575-580. PMID: 36210299.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    9. Chablani PV, Karrison T, Stadler WM. Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 Dec; 20(6):510-514. PMID: 35869002.
      Citations:    Fields:    Translation:Humans
    10. Stadler W. Emerging targets in kidney cancer: opportunities for drug development. Clin Adv Hematol Oncol. 2022 05; 20(5):299-300. PMID: 35579589.
      Citations:    Fields:    Translation:Humans
    11. Paintal A, Tjota MY, Wang P, Fitzpatrick C, Wanjari P, Stadler WM, Gallan AJ, Segal J, Antic T. NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. Am J Surg Pathol. 2022 05 01; 46(5):617-627. PMID: 35034039.
      Citations: 1     Fields:    Translation:Humans
    12. Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, Schonhoft J, Chu YL, Karrison T, Stadler WM, Szmulewitz RZ. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559. PMID: 35110415; PMCID: PMC9012680.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    13. McGregor BA, Xie W, Adib E, Stadler WM, Zakharia Y, Alva A, Michaelson MD, Gupta S, Lam ET, Farah S, Nassar AH, Wei XX, Kilbridge KL, Harshman L, Signoretti S, Sholl L, Kwiatkowski DJ, McKay RR, Choueiri TK. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448. PMID: 35171658; PMCID: PMC8865529.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    14. Stadler WM, Hlubocky FJ, Hathaway F. Knowledge and distress in complex cancer care. Cancer. 2022 04 01; 128(7):1359-1360. PMID: 34890042.
      Citations:    Fields:    Translation:Humans
    15. Heiss BL, Geynisman DM, Martinez E, Wong ASC, Yong WP, Szmulewitz RZ, Stadler WM. Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. Support Care Cancer. 2022 Mar; 30(3):2803-2810. PMID: 34845502; PMCID: PMC8830594.
      Citations: 2     Fields:    Translation:Humans
    16. Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2022 Jan 13; 3(1). PMID: 34993496; PMCID: PMC8725988.
      Citations: 10     
    17. Halabi S, Yang Q, Carmack A, Zhang S, Foo WC, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, George DJ, Armstrong AJ. Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. Kidney Cancer J. 2021 Oct; 19(3):64-72. PMID: 34765076; PMCID: PMC8580377.
      Citations: 1     
    18. Costello BA, Bhavsar NA, Zakharia Y, Pal SK, Vaishampayan U, Jim H, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Mardekian J, Borham A, George DJ, Harrison MR. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer. 2022 02; 20(1):1-10. PMID: 34364796; PMCID: PMC10186183.
      Citations: 1     Fields:    Translation:Humans
    19. Armstrong AJ, Nixon AB, Carmack A, Yang Q, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, George DJ, Halabi S. Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 Jun 15; 27(12):3503. PMID: 34117029.
      Citations: 4     Fields:    
    20. Szmulewitz RZ, Stadler WM, Ratain MJ. The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check. JAMA Oncol. 2021 06 01; 7(6):827-828. PMID: 33662094.
      Citations: 1     Fields:    Translation:Humans
    21. Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496. PMID: 33989025; PMCID: PMC8462587.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    22. Harrison MR, Costello BA, Bhavsar NA, Vaishampayan U, Pal SK, Zakharia Y, Jim HSL, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Inman BA, Mardekian J, Borham A, George DJ. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer. 2021 07 01; 127(13):2204-2212. PMID: 33765337; PMCID: PMC8251950.
      Citations: 15     Fields:    Translation:Humans
    23. Hines J, Daily E, Pham AK, Shea CR, Nadeem U, Husain AN, Stadler WM, Reid P. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. J Med Case Rep. 2021 Mar 19; 15(1):124. PMID: 33736690; PMCID: PMC7977267.
      Citations: 2     Fields:    Translation:Humans
    24. Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth J, Stadler WM, Hutson TE, Bracarda S, Choueiri TK, Reeves J, Cohn A, Ding B, Leng N, Hashimoto K, Huseni M, Schiff C, McDermott DF, Ravaud A, Suarez C. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. Eur Urol. 2021 05; 79(5):665-673. PMID: 33678522; PMCID: PMC9357270.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    25. Armstrong AJ, Nixon AB, Carmack A, Yang Q, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, George DJ, Halabi S. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 06 15; 27(12):3317-3328. PMID: 33593885.
      Citations: 9     Fields:    Translation:Humans
    26. Lee RT, Kwon N, Wu J, To C, To S, Szmulewitz R, Tchekmedyian R, Holmes HM, Olopade OI, Stadler WM, Von Roenn J. Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer. 2021 06 01; 127(11):1827-1835. PMID: 33524183.
      Citations: 13     Fields:    Translation:Humans
    27. Tjota MY, Segal J, Stadler WM, Antic T. Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case. Pathology. 2021 Oct; 53(6):790-793. PMID: 33509639.
      Citations: 2     Fields:    Translation:Humans
    28. McKay RR, McGregor BA, Xie W, Braun DA, Wei X, Kyriakopoulos CE, Zakharia Y, Maughan BL, Rose TL, Stadler WM, McDermott DF, Harshman LC, Choueiri TK. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol. 2020 12 20; 38(36):4240-4248. PMID: 33108238; PMCID: PMC7768333.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    29. Stadler WM. No interest, no conflict. Cancer. 2020 08 15; 126(16):3627-3628. PMID: 32497250.
      Citations:    Fields:    Translation:Humans
    30. Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, Wade JL, Sleckman BG, Anderson D, Brisson RJ, Karrison T, Stadler WM, Vokes EE. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243. PMID: 32365226.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    31. Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Bracarda S, Stadler WM, Donskov F, Gurney H, Oudard S, Uemura M, Lam ET, Quach C, Carroll S, Ding B, Zhu QC, Piault-Louis E, Schiff C, Escudier B, Suarez C, Grüllich C. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 06 01; 26(11):2506-2514. PMID: 32127394; PMCID: PMC8407399.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    32. Kochanny SE, Worden FP, Adkins DR, Lim DW, Bauman JE, Wagner SA, Brisson RJ, Karrison TG, Stadler WM, Vokes EE, Seiwert TY. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152. PMID: 32073648; PMCID: PMC8011819.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    33. Sagar V, Vatapalli R, Lysy B, Pamarthy S, Anker JF, Rodriguez Y, Han H, Unno K, Stadler WM, Catalona WJ, Hussain M, Gill PS, Abdulkadir SA. EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death Dis. 2019 10 22; 10(11):801. PMID: 31641103; PMCID: PMC6805914.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    34. Stadler WM. Management of Urothelial Bladder Cancer: Predicting the Future. J Oncol Pract. 2019 08; 15(8):429-430. PMID: 31404513.
      Citations: 1     Fields:    Translation:Humans
    35. Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2019 08 01; 30(8):1405. PMID: 30726873; PMCID: PMC7360153.
      Citations:    Fields:    
    36. Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Alekseev B, Uemura M, De Giorgi U, Porta C, Gurney H, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ, IMmotion151 Study Group, Suarez C, Ravaud A, Staehler M, Mellado B, Melichar B, Bedke J. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 06 15; 393(10189):2404-2415. PMID: 31079938.
      Citations: 395     Fields:    Translation:HumansCTClinical Trials
    37. Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695. PMID: 30968729; PMCID: PMC6595543.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    38. Labbate C, Hatogai K, Werntz R, Stadler WM, Steinberg GD, Eggener S, Sweis RF. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66. PMID: 30857555; PMCID: PMC6413449.
      Citations: 34     Fields:    Translation:Humans
    39. Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC, Martínez Chanzá N. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 04; 20(4):581-590. PMID: 30827746; PMCID: PMC6849381.
      Citations: 57     Fields:    Translation:Humans
    40. Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Kavitt RT, Meltzer DO, Ratain MJ, O'Donnell PH. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537. PMID: 30713337; PMCID: PMC6980369.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    41. Borden BA, Galecki P, Wellmann R, Danahey K, Lee SM, Patrick-Miller L, Sorrentino MJ, Nanda R, Koyner JL, Polonsky TS, Stadler WM, Mulcahy C, Kavitt RT, Ratain MJ, Meltzer DO, O'Donnell PH. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 02; 29(2):31-38. PMID: 30531377.
      Citations: 12     Fields:    Translation:Humans
    42. Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836. PMID: 30707764.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    43. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Bracarda S, Danielli R, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T, Ravaud A, Suárez C, Gruenwald V. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Dec; 24(12):1941. PMID: 30291359.
      Citations: 13     Fields:    
    44. Sweis RF, Heiss B, Segal J, Ritterhouse L, Kadri S, Churpek JE, Allen K, Conway D, Marinier C, Smith ND, Pitroda SP, Stadler WM. Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations. JCO Precis Oncol. 2018 Nov; 2:1-7. PMID: 35135165.
      Citations: 7     Fields:    
    45. Szmulewitz RZ, Stadler WM, Ratain MJ. Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. J Clin Oncol. 2018 10 20; 36(30):3064-3065. PMID: 30188784.
      Citations:    Fields:    Translation:Humans
    46. Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJ. Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061. PMID: 30188785.
      Citations: 3     Fields:    Translation:Humans
    47. Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, Stadler WM, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018; 2018. PMID: 30761386; PMCID: PMC6370313.
      Citations: 12     Fields:    
    48. Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 10; 36(5):919-926. PMID: 30083962; PMCID: PMC6153554.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    49. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Bracarda S, Danielli R, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T, Ravaud A, Suárez C, Gruenwald V. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 06; 24(6):749-757. PMID: 29867230; PMCID: PMC6721896.
      Citations: 505     Fields:    Translation:HumansCTClinical Trials
    50. Wellmann R, Borden BA, Danahey K, Nanda R, Polite BN, Stadler WM, Ratain MJ, O'Donnell PH. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065. PMID: 29742281; PMCID: PMC6354920.
      Citations: 7     Fields:    Translation:Humans
    51. Jelinek MJ, Lee SM, Wyche Okpareke A, Wing C, Koyner JL, Murray PT, Stadler WM, O' Donnell PH. Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C. Clin Transl Sci. 2018 07; 11(4):420-427. PMID: 29691991; PMCID: PMC6039203.
      Citations: 4     Fields:    Translation:Humans
    52. Danzig MR, Mallin K, McKiernan JM, Stadler WM, Sridhar SS, Morgan TM, Bochner BH, Lee CT. Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer. 2018 06 15; 124(12):2507-2514. PMID: 29624636; PMCID: PMC8248269.
      Citations: 6     Fields:    Translation:Humans
    53. Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395. PMID: 29590007; PMCID: PMC5941614.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    54. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018 04; 73(4):560-569. PMID: 29325693.
      Citations: 177     Fields:    Translation:Humans
    55. Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 04 01; 36(10):991-999. PMID: 29261439; PMCID: PMC6075827.
      Citations: 95     Fields:    Translation:HumansCellsCTClinical Trials
    56. Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2018 06; 16(3):213-218. PMID: 29289519; PMCID: PMC6731031.
      Citations: 2     Fields:    Translation:Humans
    57. Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573. PMID: 28832978; PMCID: PMC5726867.
      Citations: 25     Fields:    Translation:Humans
    58. O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Strek ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KT, Leung E, Volchenboum SL, Altman RB, Olopade OI, Stadler WM, Meltzer DO, Ratain MJ. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869. PMID: 28398598; PMCID: PMC5636653.
      Citations: 33     Fields:    Translation:Humans
    59. Galanina N, Petrich A, Gartenhaus R, Westin JR, Knost JA, Doyle A, Gordon LI, Evens AM, Smith SM, Liao C, Libao B, Cohen KS, Stadler WM, Karrison T. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267. PMID: 28419407; PMCID: PMC5785463.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    60. McKillip RP, Borden BA, Galecki P, Ham SA, Patrick-Miller L, Hall JP, Hussain S, Danahey K, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Ratain MJ, Meltzer DO, O'Donnell PH. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114. PMID: 27981566; PMCID: PMC5474215.
      Citations: 11     Fields:    Translation:Humans
    61. Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL, Marté JL. Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget. 2016 10 18; 7(42):69014-69023. PMID: 27486817; PMCID: PMC5340090.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    62. Drazer MW, Stadler WM. The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. Cancer J. 2016 Sep/Oct; 22(5):330-333. PMID: 27749326; PMCID: PMC5108565.
      Citations: 5     Fields:    Translation:Humans
    63. Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WM. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212. PMID: 27634566; PMCID: PMC5315677.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    64. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8. PMID: 27197067; PMCID: PMC4943758.
      Citations: 185     Fields:    Translation:HumansCells
    65. Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471. PMID: 27169994; PMCID: PMC5106340.
      Citations: 142     Fields:    Translation:HumansCellsCTClinical Trials
    66. Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, Karrison T, Stadler WM, Nakamura Y, O'Donnell PH. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71. PMID: 27044931; PMCID: PMC5569685.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    67. Chen Y, Rini BI, Motzer RJ, Dutcher JP, Rixe O, Wilding G, Stadler WM, Tarazi J, Garrett M, Pithavala YK. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Target Oncol. 2016 Apr; 11(2):229-34. PMID: 26400730; PMCID: PMC5568082.
      Citations: 7     Fields:    Translation:Humans
    68. O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer. 2016 12; 14(6):511-517. PMID: 27150640; PMCID: PMC5018246.
      Citations: 2     Fields:    Translation:Humans
    69. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16. PMID: 26969090; PMCID: PMC4878938.
      Citations: 228     Fields:    Translation:HumansCTClinical Trials
    70. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ, Prostate Cancer Clinical Trials Working Group 3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18. PMID: 26903579; PMCID: PMC4872347.
      Citations: 508     Fields:    Translation:Humans
    71. Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar; 17(3):378-388. PMID: 26794930; PMCID: PMC6863151.
      Citations: 146     Fields:    Translation:HumansCTClinical Trials
    72. Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, Cohen LJ. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016 Jan; 77(1):155-62. PMID: 26576779.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    73. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92. PMID: 26527777; PMCID: PMC4678179.
      Citations: 240     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    74. Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL, Shen J, Gururajan M, Sievert M, Stadler WM. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93. PMID: 26493492; PMCID: PMC4904773.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    75. Stein MN, Hussain M, Stadler WM, Liu G, Tereshchenko IV, Goodin S, Jeyamohan C, Kaufman HL, Mehnert J, DiPaola RS. A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer. 2016 Feb; 14(1):22-7. PMID: 26476589; PMCID: PMC4698193.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    76. Mata DA, Groshen S, Von Rundstedt FC, Skinner DG, Stadler WM, Cote RJ, Stein JP, Lerner SP. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun; 111(7):923-8. PMID: 25873574; PMCID: PMC4602027.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    77. Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 07; 26(7):1459-64. PMID: 25858498; PMCID: PMC4478972.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    78. von Rundstedt FC, Mata DA, Groshen S, Stein JP, Skinner DG, Stadler WM, Cote RJ, Kryvenko ON, Godoy G, Lerner SP. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9. PMID: 25413313; PMCID: PMC4524781.
      Citations: 8     Fields:    Translation:Humans
    79. Halabi S, Rini BI, Escudier B, Stadler WM, Small EJ. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 01; 121(11):1906. PMID: 25677867.
      Citations:    Fields:    Translation:Humans
    80. Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, Stadler WM, Vander Griend DJ, Szmulewitz RZ. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014 Nov 26; 12:313. PMID: 25424879; PMCID: PMC4252013.
      Citations: 26     Fields:    Translation:HumansCells
    81. Milowsky MI, Dittrich C, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN, Durán I. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52. PMID: 25457633.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    82. Armstrong AJ, Kaboteh R, Carducci MA, Damber JE, Stadler WM, Hansen M, Pili R, Morris MJ, Edenbrandt L, Forsberg G, Nordle Ö. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol. 2014 Nov; 32(8):1308-16. PMID: 25240761; PMCID: PMC6341998.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    83. VanderWeele DJ, Brown CD, Taxy JB, Gillard M, Hatcher DM, Tom WR, Stadler WM, White KP. Low-grade prostate cancer diverges early from high grade and metastatic disease. Cancer Sci. 2014 Aug; 105(8):1079-85. PMID: 24890684; PMCID: PMC4317857.
      Citations: 30     Fields:    Translation:Humans
    84. Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Hasseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014 Aug; 5(4):232-9. PMID: 24849545; PMCID: PMC4298824.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    85. Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G, Niegisch G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43. PMID: 24219029.
      Citations: 17     Fields:    Translation:Humans
    86. Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ, Smith MR. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50. PMID: 24590644; PMCID: PMC3970172.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    87. Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, Schwartz JD, Thompson JA. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 2014 Jun 01; 120(11):1647-55. PMID: 24577874.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    88. Stadler WM. Maturing of renal cancer therapeutics. J Clin Oncol. 2014 Mar 10; 32(8):722-4. PMID: 24516015.
      Citations: 3     Fields:    Translation:Humans
    89. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. PMID: 24418642.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    90. Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin CC, Mahoney J, Modi S, Lee P, Ernstoff MS, Su WC, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. 2014 Apr 01; 120(7):976-82. PMID: 24339028; PMCID: PMC4696031.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    91. Golden DW, Corbin KS, Hasselle MD, Liauw SL, Stadler WM, Hahn OM, Weichselbaum RR, Salama JK, Ranck MC. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95. PMID: 22868242.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    92. Armstrong AJ, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Forsberg G, Carducci MA, Pili R, Häggman M, Nordle Ö. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Dec 15; 19(24):6891-901. PMID: 24255071; PMCID: PMC4251453.
      Citations: 26     Fields:    Translation:Humans
    93. Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar 01; 120(5):692-701. PMID: 24249435.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    94. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8. PMID: 24178622; PMCID: PMC4310865.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    95. Halabi S, Rini B, Escudier B, Stadler WM, Small EJ. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014 Jan 01; 120(1):52-60. PMID: 24347384; PMCID: PMC3869105.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    96. Michaelson MD, Stadler WM. Predictive markers in advanced renal cell carcinoma. Semin Oncol. 2013 Aug; 40(4):459-64. PMID: 23972709.
      Citations: 8     Fields:    Translation:Humans
    97. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ, Alliance for Clinical Trials in Oncology. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43. PMID: 23913744; PMCID: PMC3795898.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    98. Chen JL, Appelbaum DE, Kocherginsky M, Cowey CL, Rathmell WK, McDermott DF, Stadler WM. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013 Aug; 2(4):545-52. PMID: 24156027; PMCID: PMC3799289.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    99. Willett LL, Estrada CA, Adams M, Arora V, Call S, Chacko K, Chaudhry S, Halvorsen AJ, Hopkins R, McDonald FS. Challenges with continuity clinic and core faculty accreditation requirements. Am J Med. 2013 Jun; 126(6):550-6. PMID: 25193772.
      Citations:    
    100. Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013 May; 53(5):491-504. PMID: 23553560; PMCID: PMC4175417.
      Citations: 56     Fields:    Translation:Humans
    101. Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, Watson S, Eggener S. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40. PMID: 23440319.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    102. Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51. PMID: 23443753; PMCID: PMC3791430.
      Citations: 6     Fields:    
    103. Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr; 63(4):717-23. PMID: 23206856; PMCID: PMC4127896.
      Citations: 59     Fields:    Translation:Humans
    104. Geynisman DM, Szmulewitz RZ, Stadler WM. A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer. Eur Urol. 2012 Nov; 62(5):864-6. PMID: 22939385.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    105. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladd. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66. PMID: 22917984.
      Citations: 84     Fields:    Translation:Humans
    106. Haney CR, Fan X, Markiewicz E, Mustafi D, Karczmar GS, Stadler WM. Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis. Technol Cancer Res Treat. 2013 Feb; 12(1):71-8. PMID: 22905809.
      Citations: 6     Fields:    Translation:HumansAnimals
    107. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80. PMID: 22831987; PMCID: PMC4319647.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    108. Liauw SL, Pitroda SP, Eggener SE, Stadler WM, Pelizzari CA, Vannier MW, Oto A. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84. PMID: 22717242.
      Citations: 32     Fields:    Translation:Humans
    109. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE, Jänne PA. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. PMID: 22665541; PMCID: PMC3397785.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    110. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 01; 30(13):1534-40. PMID: 22454414; PMCID: PMC3383121.
      Citations: 238     Fields:    Translation:HumansCTClinical Trials
    111. O'Donnell PH, Stadler WM. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer Res. 2012 May 15; 18(10):2809-16. PMID: 22427349; PMCID: PMC3354016.
      Citations: 4     Fields:    Translation:Humans
    112. Stadler WM. Renal cancer therapeutics: now what? Oncology (Williston Park). 2012 Mar; 26(3):301, 304. PMID: 22545315.
      Citations:    Fields:    Translation:Humans
    113. Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15. PMID: 22287601; PMCID: PMC3328614.
      Citations: 15     Fields:    Translation:Humans
    114. Stadler WM. Optimal use of imaging to guide treatment decisions for kidney cancer. Am Soc Clin Oncol Educ Book. 2012; 284-7. PMID: 24451750.
      Citations:    Fields:    
    115. Karrison TG, Ratain MJ, Stadler WM, Rosner GL. Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design. Am Stat. 2012; 66(3):155-162. PMID: 24039273; PMCID: PMC3769804.
      Citations: 2     
    116. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, Stadler WM. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90. PMID: 22109293.
      Citations: 92     Fields:    Translation:Humans
    117. Lussier YA, Stadler WM, Chen JL. Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. J Am Med Inform Assoc. 2012 Mar-Apr; 19(2):156-60. PMID: 22101905; PMCID: PMC3277616.
      Citations: 19     Fields:    Translation:Humans
    118. Kayhan A, Yang C, Soylu FN, Lakadamyali H, Sethi I, Karczmar G, Stadler W, Oto A. Dynamic contrast-enhanced MR imaging findings of bone metastasis in patients with prostate cancer. World J Radiol. 2011 Oct 28; 3(10):241-5. PMID: 22229077; PMCID: PMC3252556.
      Citations: 8     
    119. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70. PMID: 22020702.
      Citations: 126     Fields:    Translation:HumansCTClinical Trials
    120. Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EM. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92. PMID: 22006050; PMCID: PMC4312616.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    121. Pili R, Stadler WM, Gingrich JR, Assikis VJ, Nordle O, Forsberg G, Carducci MA, Armstrong AJ, Häggman M, Björk A. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011 Oct 20; 29(30):4022-8. PMID: 21931019.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    122. Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, Hall C, Skinner DG, Cote RJ. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9. PMID: 21810677; PMCID: PMC3164246.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    123. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30. PMID: 21762967; PMCID: PMC3166448.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    124. Chen JL, Li J, Stadler WM, Lussier YA. Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. J Am Med Inform Assoc. 2011 Jul-Aug; 18(4):392-402. PMID: 21672909; PMCID: PMC3128407.
      Citations: 20     Fields:    Translation:HumansCells
    125. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100. PMID: 21709274; PMCID: PMC3139588.
      Citations: 33     Fields:    Translation:Humans
    126. Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen SD. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012 Feb 01; 72(2):157-64. PMID: 21563193; PMCID: PMC6000822.
      Citations: 34     Fields:    Translation:Humans
    127. Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S, Sleckman BG, Taber D, Vokes EE, Stadler WM, Kindler HL. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5. PMID: 21552992; PMCID: PMC4317401.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    128. Trask PC, Bushmakin AG, Cappelleri JC, Tarazi J, Rosbrook B, Bycott P, Kim S, Stadler WM, Rini B. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv. 2011 Sep; 5(3):255-62. PMID: 21476015.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    129. Chung EK, Posadas EM, Kasza K, Karrison T, Manchen E, Hahn OM, Stadler WM. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4. PMID: 20395787; PMCID: PMC4644601.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    130. Cohen EE, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, Stadler WM, Ratain MJ. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9. PMID: 21439817; PMCID: PMC4116678.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    131. Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ, Hoosier Oncology Group. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011 Apr 20; 29(12):1525-30. PMID: 21422406.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    132. Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W. Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. Urology. 2011 Apr; 77(4):934-40. PMID: 21269665; PMCID: PMC3074039.
      Citations: 26     Fields:    Translation:Humans
    133. Nabhan C, Parsons B, Touloukian EZ, Stadler WM. Novel approaches and future directions in castration-resistant prostate cancer. Ann Oncol. 2011 Sep; 22(9):1948-1957. PMID: 21252057.
      Citations: 9     Fields:    Translation:Humans
    134. Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F, Schöffski P. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86. PMID: 21156020.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    135. Ward JE, Stadler WM. Pazopanib in renal cell carcinoma. Clin Cancer Res. 2010 Dec 15; 16(24):5923-7. PMID: 21059813.
      Citations: 14     Fields:    Translation:HumansAnimals
    136. Stadler WM, Phillips G, George DJ, Halabi S, Small E. Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol. 2010 Nov 20; 28(33):e692-3; author reply e694. PMID: 20940194.
      Citations: 2     Fields:    Translation:Humans
    137. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, Cote RJ. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res. 2010 Oct 15; 16(20):5011-8. PMID: 20876796; PMCID: PMC2955786.
      Citations: 180     Fields:    Translation:HumansCells
    138. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ, Cancer and Leukemia Group B. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011 Feb 01; 117(3):526-33. PMID: 20862750; PMCID: PMC3010428.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    139. Oto A, Kayhan A, Jiang Y, Tretiakova M, Yang C, Antic T, Dahi F, Shalhav AL, Karczmar G, Stadler WM. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology. 2010 Dec; 257(3):715-23. PMID: 20843992; PMCID: PMC6939960.
      Citations: 105     Fields:    Translation:Humans
    140. O'Donnell PH, Undevia SD, Stadler WM, Karrison TM, Nicholas MK, Janisch L, Ratain MJ. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10. PMID: 20839028; PMCID: PMC3059335.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    141. Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6. PMID: 20803052; PMCID: PMC4319645.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    142. Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology. 2010; 78(5-6):340-7. PMID: 20733337.
      Citations: 11     Fields:    Translation:Humans
    143. Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, Stadler WM. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol. 2010 Aug; 75(2):152-9. PMID: 20656210; PMCID: PMC3028591.
      Citations: 22     Fields:    Translation:Humans
    144. Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, Stadler WM. WITHDRAWN: Cognitive effects of androgen deprivation therapy in an older cohort of men with prostrate cancer. Crit Rev Oncol Hematol. 2010 Jul 01. PMID: 20427196.
      Citations:    Fields:    
    145. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. PMID: 20646741; PMCID: PMC2952720.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    146. Yang C, Stadler WM, Karczmar GS, Milosevic M, Yeung I, Haider MA. Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT. Magn Reson Med. 2010 Jun; 63(6):1601-9. PMID: 20512864; PMCID: PMC3089960.
      Citations: 10     Fields:    Translation:Humans
    147. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 01; 28(13):2137-43. PMID: 20368558; PMCID: PMC2860433.
      Citations: 291     Fields:    Translation:HumansCTClinical Trials
    148. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR, Biomarkers Task Force of the NCI Investigational Drug Steering Committee. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55. PMID: 20215558.
      Citations: 105     Fields:    Translation:Humans
    149. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010 Mar 01; 116(5):1272-80. PMID: 20082451.
      Citations: 92     Fields:    Translation:Humans
    150. O'Donnell PH, Jensen A, Posadas EM, Bridge JA, Yeldandi AV, Yang XJ, Stadler WM, Al-Ahmadie H. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol. 2010 Feb; 7(2):110-4. PMID: 20145663.
      Citations: 4     Fields:    Translation:Humans
    151. Stadler WM. Prognosis and prediction in a Facebook world. Cancer. 2009 Dec 01; 115(23):5368-70. PMID: 19658183.
      Citations:    Fields:    Translation:Humans
    152. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer. 2009 Dec 01; 115(23):5541-9. PMID: 19711464; PMCID: PMC2917101.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    153. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ, Ratain MJ. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7. PMID: 19773379; PMCID: PMC2756980.
      Citations: 71     Fields:    Translation:HumansCells
    154. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V, George C. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009 Sep 15; 115(18):4110-7. PMID: 19536904.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    155. Stadler W. Other paradigms: randomized discontinuation trial design. Cancer J. 2009 Sep-Oct; 15(5):431-4. PMID: 19826364.
      Citations: 4     Fields:    Translation:Humans
    156. Liauw SL, Stadler WM, Correa D, Weichselbaum RR, Jani AB. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):125-30. PMID: 19695789; PMCID: PMC3049990.
      Citations: 4     Fields:    Translation:Humans
    157. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20; 27(27):4462-8. PMID: 19652060.
      Citations: 129     Fields:    Translation:HumansCTClinical Trials
    158. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, Riggs CE, Higano C, Stadler WM, McCulloch W, Dearnaley D, Parker C, de Bono JS. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2010 Jan; 21(1):109-13. PMID: 19608618.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    159. Stadler WM. Effective therapy for metastatic renal cancer, whither to now. J Clin Oncol. 2009 Aug 01; 27(22):3573-4. PMID: 19487371.
      Citations: 1     Fields:    Translation:Humans
    160. Escudier B, Eisen T, Stadler WM, Szczylik C, Staehler M, Negrier S, Chevreau C, Desai AA, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM, Oudard S, Rolland F. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10; 27(20):3312-8. PMID: 19451442.
      Citations: 387     Fields:    Translation:HumansCTClinical Trials
    161. Yang C, Karczmar GS, Medved M, Oto A, Zamora M, Stadler WM. Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9. PMID: 19185002; PMCID: PMC2758034.
      Citations: 24     Fields:    Translation:Humans
    162. Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J Clin Oncol. 2009 Apr 01; 27(10):1557-63. PMID: 19255325; PMCID: PMC2738613.
      Citations: 18     Fields:    Translation:Humans
    163. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. PMID: 19396016; PMCID: PMC3225398.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    164. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103. PMID: 19282098; PMCID: PMC2885777.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    165. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34. PMID: 19228743; PMCID: PMC3147153.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    166. Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF, Stadler WM. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate. 2009 Feb 01; 69(2):142-8. PMID: 18942640.
      Citations: 3     Fields:    Translation:HumansCells
    167. O'Donnell PH, Stadler WM. The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol. 2009; 419028. PMID: 19190766; PMCID: PMC2630419.
      Citations: 8     
    168. Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer. 2009 Jan; 7(1):39-42. PMID: 19213667.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    169. Chung EK, Stadler WM. Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. Clin Genitourin Cancer. 2008 Dec; 6 Suppl 1:S22-8. PMID: 19891126.
      Citations: 4     Fields:    Translation:HumansCells
    170. Milowsky MI, Stadler WM, Bajorin DF. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int. 2008 Nov; 102(9 Pt B):1339-44. PMID: 19035902.
      Citations: 9     Fields:    Translation:Humans
    171. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20; 26(33):5422-8. PMID: 18936475; PMCID: PMC2651074.
      Citations: 337     Fields:    Translation:HumansCTClinical Trials
    172. Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, Limacher JM, Squiban P, Pantuck A. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs. 2009 Aug; 27(4):379-86. PMID: 18931824.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    173. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R. FYN is overexpressed in human prostate cancer. BJU Int. 2009 Jan; 103(2):171-7. PMID: 18990162; PMCID: PMC2741693.
      Citations: 47     Fields:    Translation:HumansCells
    174. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8. PMID: 18824708; PMCID: PMC2736992.
      Citations: 97     Fields:    Translation:Humans
    175. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9. PMID: 18698045.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    176. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 01; 26(22):3743-8. PMID: 18669461.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    177. Jonasch E, Stadler WM, Bukowski RM, Hayes TG, Varadhachary A, Malik R, Figlin RA, Srinivas S. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008 Jul 01; 113(1):72-7. PMID: 18484647.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    178. Stadler W. Angiogenesis inhibition in non-clear cell renal cancer. Clin Adv Hematol Oncol. 2008 Jul; 6(7):507-9. PMID: 18654117.
      Citations:    Fields:    Translation:Humans
    179. Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M, Mohile SG. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology. 2008 Aug; 72(2):422-7. PMID: 18561991; PMCID: PMC3032402.
      Citations: 52     Fields:    Translation:Humans
    180. Dutcher JP, Wilding G, Hudes GR, Stadler WM, Kim S, Tarazi JC, Rosbrook B, Rini BI. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol. 2008 May 20; 26(15_suppl):5127. PMID: 27948026.
      Citations:    
    181. Lee RT, Qato D, Curlin F, Stadler WM, Lindau ST. Older cancer survivors' use of biologically based complementary and alternative medicine (CAM): A national, population-based study in the United States. J Clin Oncol. 2008 May 20; 26(15_suppl):9508. PMID: 27948197.
      Citations:    
    182. Wiebe L, Kasza KE, Maki RG, D'Adamo DR, Chow WA, Wade Iii JL, Agamah E, Stadler WM, Vokes EE, Kindler HL. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol. 2008 May 20; 26(15_suppl):10502. PMID: 27948416.
      Citations:    
    183. Bukowski RM, Stadler WM, Figlin RA, Knox JJ, Gabrail N, McDermott DF, Cupit L, Miller WH, Hainsworth JD, Ryan CW. Safety and efficacy of sorafenib in elderly patients (pts) =65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. J Clin Oncol. 2008 May 20; 26(15_suppl):5045. PMID: 27948865.
      Citations:    
    184. Kindler HL, Gangadhar T, Karrison T, Hochster HS, Moore MJ, Micetich K, Sun W, Catenacci DV, Stadler WM, Vokes EE. Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). J Clin Oncol. 2008 May 20; 26(15_suppl):4502. PMID: 27949226.
      Citations:    
    185. Gofrit ON, Stadler WM, Zorn KC, Lin S, Silvestre J, Shalhav AL, Zagaja GP, Steinberg GD. Adjuvant chemotherapy in lymph node positive bladder cancer. Urol Oncol. 2009 Mar-Apr; 27(2):160-4. PMID: 18440835.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    186. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF, Chicago Phase II Consortium, PMH Phase II Consortium, California Phase II Consortium. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55. PMID: 18423560; PMCID: PMC2699608.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    187. Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Southwest Oncology Group, Glodé LM. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20; 26(9):1532-6. PMID: 18349405.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    188. Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas SP, Nichols KF, Stadler WM. A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer. 2008 Mar; 6(1):21-4. PMID: 18501078; PMCID: PMC2704464.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    189. Lassiter LK, Tummala MK, Hussain MH, Stadler WM, Petrylak DP, Carducci MA. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. Clin Genitourin Cancer. 2008 Mar; 6(1):31-5. PMID: 18501080.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    190. Bylow K, Mohile SG, Stadler WM, Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer. 2007 Dec 15; 110(12):2604-13. PMID: 17960609.
      Citations: 41     Fields:    Translation:Humans
    191. Yang C, Karczmar GS, Medved M, Stadler WM. Multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med. 2007 Dec; 58(6):1266-75. PMID: 17969061.
      Citations: 29     Fields:    Translation:Humans
    192. Bradley DA, Dunn R, Nanus D, Stadler W, Dreicer R, Rosenberg J, Smith DC, Hussain M. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer. 2007 Dec; 5(7):460-3. PMID: 18272031.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    193. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer. 2008 Jan; 44(1):8-11. PMID: 17981025; PMCID: PMC2673461.
      Citations: 11     Fields:    Translation:Humans
    194. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61. PMID: 17895472.
      Citations: 67     Fields:    Translation:Humans
    195. Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, Stadler W, Rinker-Schaeffer CW. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J Pathol. 2007 Aug; 212(4):386-94. PMID: 17577251.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    196. Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int. 2007 Jul; 100(1):70-5. PMID: 17552955.
      Citations: 19     Fields:    Translation:Humans
    197. Stadler WM, Szmulewitz RZ. Sunitinib--a new standard of care for metastatic renal cell carcinoma. Nat Clin Pract Oncol. 2007 Aug; 4(8):458-9. PMID: 17593923.
      Citations: 2     Fields:    
    198. Stadler WM, Desai AA, Quinn DI, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94. PMID: 17569043.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    199. Knight DA, Stadler WM. Prognostic factors in localized renal cell cancer. BJU Int. 2007 May; 99(5 Pt B):1212-6. PMID: 17441913.
      Citations: 5     Fields:    Translation:Humans
    200. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51. PMID: 17458505.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    201. Stadler WM. The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. Mol Cancer Ther. 2007 Apr; 6(4):1180-5. PMID: 17431101.
      Citations: 8     Fields:    Translation:Humans
    202. Posadas EM, Undevia S, Manchen E, Wade JL, Colevas AD, Karrison T, Vokes EE, Stadler WM. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3. PMID: 17457044.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    203. Stadler W. Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development. Clin Cancer Res. 2007 Mar 15; 13(6):1630-3. PMID: 17363513.
      Citations: 5     Fields:    Translation:HumansCells
    204. Stadler W. Fuzzy thinking on biomarkers. Urol Oncol. 2007 Mar-Apr; 25(2):97-100. PMID: 17349522.
      Citations: 1     Fields:    Translation:Humans
    205. Furge KA, Tan MH, Dykema K, Kort E, Stadler W, Yao X, Zhou M, Teh BT. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene. 2007 Feb 26; 26(9):1346-50. PMID: 17322920.
      Citations: 17     Fields:    Translation:Humans
    206. Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007 Feb 15; 109(4):802-10. PMID: 17219443.
      Citations: 69     Fields:    Translation:Humans
    207. Escudier B, Eisen T, Stadler WM, Szczylik C, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group, Oudard S, Rolland F. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11; 356(2):125-34. PMID: 17215530.
      Citations: 1714     Fields:    Translation:HumansCTClinical Trials
    208. Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007 Jan; 69(1 Suppl):62-79. PMID: 17280909.
      Citations: 64     Fields:    Translation:Humans
    209. Furge KA, Kort EJ, Yang XJ, Stadler WM, Kim H, Teh BT. Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses. Clin Genitourin Cancer. 2006 Dec; 5(3):227-31. PMID: 17239277.
      Citations: 1     Fields:    Translation:HumansCells
    210. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol. 2006 Nov; 18(6):615-21. PMID: 16988583.
      Citations: 20     Fields:    Translation:Humans
    211. Gomez-Abuin G, Winquist E, Stadler WM, Pond G, Degendorfer P, Wright J, Moore MJ. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs. 2007 Apr; 25(2):181-5. PMID: 16983508.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    212. Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ, Cancer and Leukemia Group B. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006 Sep 15; 107(6):1273-9. PMID: 16909426.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    213. Jin JO, Lehmann J, Taxy J, Huo D, Vogelzang NJ, Steinberg G, Stadler WM, Stöckle M. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):150-4. PMID: 17026804.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    214. Stadler WM. Development of growth inhibitory agents in urological and other malignancies. BJU Int. 2006 Sep; 98(3):497-502. PMID: 16827906.
      Citations:    Fields:    Translation:Humans
    215. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, Stadler WM. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov; 31(6):783-5. PMID: 16824050.
      Citations: 8     Fields:    Translation:Humans
    216. Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T, Stadler WM, McCarthy PL, Linker CA, Small EJ, Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, Southwestern Oncology Group. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant. 2006 Jul; 12(7):778-85. PMID: 16785067.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    217. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006 Jun; 5(1):57-60. PMID: 16859580.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    218. Stadler W. New therapeutic options for renal cell carcinoma. Clin Adv Hematol Oncol. 2006 Jun; 4(6):429-30. PMID: 16981664.
      Citations: 1     Fields:    Translation:Humans
    219. Small EJ, Halabi S, Kantoff P, D'Amico A, Stadler W, Kelley WK, Mohler J, Bajorin D, Vogelzang NJ. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3596s-600s. PMID: 16740791.
      Citations: 1     Fields:    Translation:Humans
    220. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12. PMID: 16636341.
      Citations: 240     Fields:    Translation:HumansCTClinical Trials
    221. Peterson AC, Harlin H, Karrison T, Vogelzang NJ, Knost JA, Kugler JW, Lester E, Vokes E, Gajewski TF, Stadler WM, University of Chicago Phase II Consortium. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9. PMID: 16514482.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    222. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. PMID: 16533781.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    223. Polite BN, Desai AA, Manchen B, Stadler WM. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer. 2006 Mar; 4(4):275-80. PMID: 16729911.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    224. Desai AA, Stadler WM. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Urol Rep. 2006 Jan; 7(1):16-22. PMID: 16480664.
      Citations: 3     Fields:    
    225. Shaheen PE, Stadler W, Elson P, Knox J, Winquist E, Bukowski RM. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs. 2005 Dec; 23(6):577-81. PMID: 16034517.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    226. Vander Griend DJ, Kocherginsky M, Hickson JA, Stadler WM, Lin A, Rinker-Schaeffer CW. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res. 2005 Dec 01; 65(23):10984-91. PMID: 16322247.
      Citations: 44     Fields:    Translation:AnimalsCells
    227. Stadler WM. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 2005 Dec 01; 104(11):2323-33. PMID: 16240452.
      Citations: 36     Fields:    Translation:Humans
    228. Stadler WM. New targets, therapies, and toxicities: lessons to be learned. J Clin Oncol. 2006 Jan 01; 24(1):4-5. PMID: 16314613.
      Citations: 5     Fields:    Translation:Humans
    229. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40. PMID: 16258101.
      Citations: 148     Fields:    Translation:HumansCTClinical Trials
    230. Stadler WM, Michaelis LC, Ratain MJ. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6. PMID: 16258115.
      Citations:    Fields:    Translation:Humans
    231. Davis NB, Ryan CW, Stadler WM, Vogelzang NJ. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int. 2005 Oct; 96(6):787-90. PMID: 16153201.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    232. Mohile SG, Stadler WM. Do elderly patients have a worse outcome in response to platinum-based therapy for metastatic urothelial cancer? Nat Clin Pract Oncol. 2005 Aug; 2(8):392-3. PMID: 16130933.
      Citations: 1     Fields:    
    233. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005 Jul 01; 65(13):5628-37. PMID: 15994935.
      Citations: 68     Fields:    Translation:Humans
    234. Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32. PMID: 15923569.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    235. Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, Stadler WM, Vokes EE. A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). J Clin Oncol. 2005 Jun; 23(16_suppl):7019. PMID: 27944450.
      Citations:    
    236. Ryan C, Stadler WM, Roth BJ, Puchalski TA, Koehler M, Small EJ. Safety and tolerability of AZD2171, a highly potent VEGFR inhibitor, in patients with advanced prostate adenocarcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):3049. PMID: 27945798.
      Citations:    
    237. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong HQ, Schwartz B, O'Dwyer P. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4544. PMID: 27946352.
      Citations:    
    238. Lara PN, Longmate J, Stadler W, van Loan M, Wexler J, Quinn DI, Twardowski P, Vokes EE, Gandara DR. Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & University of Chicago trial. J Clin Oncol. 2005 Jun; 23(16_suppl):4569. PMID: 27946388.
      Citations:    
    239. Stadler WM, Swerdloff JN, Margolin K, McCulloch B, Thompson J. A phase II study of depsipeptide (Dep) in patients (pts) with metastatic renal cell cancer (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4669. PMID: 27946801.
      Citations:    
    240. Sridhar SS, Stadler W, Le L, Hedley D, Pond G, Wright J, Vokes E, Thomas S, Moore M. Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium. J Clin Oncol. 2005 Jun; 23(16_suppl):4677. PMID: 27946832.
      Citations:    
    241. Polite BN, Desai AA, Peterson AC, Manchen B, Stadler WM. A phase II study of imatinib mesylate (IM) and interferon-alpha (IFNA) in metastatic renal cell carcinoma (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4689. PMID: 27946842.
      Citations:    
    242. Jin JO, Lehmann J, Stockle M, Steinberg G, Stadler W. Phase II trial of adjuvant gemcitabine plus cisplatin (GC) with amifostine cytoprotection in patients (pts) with locally advanced bladder cancer (BC). J Clin Oncol. 2005 Jun; 23(16_suppl):4695. PMID: 27946863.
      Citations:    
    243. Ryan CW, Stadler WM, Vogelzang NJ. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. BJU Int. 2005 May; 95(7):963-8. PMID: 15839914.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    244. Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, Stadler WM. A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol. 2005 May-Jun; 23(3):150-4. PMID: 15907713.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    245. Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65. PMID: 15824081.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    246. Artz A, Stadler WM, Vogelzang NJ, Zimmerman T, Ryan C. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol. 2005 Apr; 28(2):109-13. PMID: 15803001.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    247. Desai AA, Stadler WM. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep. 2005 Mar; 7(2):116-22. PMID: 15717945.
      Citations: 2     Fields:    Translation:Humans
    248. Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60. PMID: 15543195.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    249. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes G, Trepicchio WL, Strahs A, Immermann F, Slonim DK, Dorner AJ. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res. 2005 Feb 01; 11(3):1181-9. PMID: 15709187.
      Citations: 51     Fields:    Translation:HumansCells
    250. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):678-89. PMID: 15701856.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    251. Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC, Cancer and Leukemia Group B. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8. PMID: 15484217.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    252. Yang C, Karczmar GS, Medved M, Stadler WM. Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Magn Reson Med. 2004 Nov; 52(5):1110-7. PMID: 15508148.
      Citations: 44     Fields:    
    253. Jani AB, Sokoloff M, Shalhav A, Stadler W. Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis. Urology. 2004 Nov; 64(5):976-81. PMID: 15533489.
      Citations:    Fields:    Translation:Humans
    254. Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S. PMID: 15448017.
      Citations: 8     Fields:    Translation:Humans
    255. Stadler WM. Therapeutic options for variant renal cancer: a true orphan disease. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6393S-6S. PMID: 15448037.
      Citations: 1     Fields:    Translation:Humans
    256. Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urol Oncol. 2004 Sep-Oct; 22(5):398-403. PMID: 15464920.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    257. Stadler WM. Cytotoxic chemotherapy for metastatic renal cell carcinoma. Urologe A. 2004 Sep; 43 Suppl 3:S145-6. PMID: 15164180.
      Citations: 2     Fields:    Translation:Humans
    258. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WM. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004 Sep-Oct; 22(5):393-7. PMID: 15464919.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    259. Berger JC, Vander Griend D, Stadler WM, Rinker-Schaeffer C. Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells. Anticancer Drugs. 2004 Jul; 15(6):559-68. PMID: 15205597.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    260. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8. PMID: 15221817.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    261. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14. PMID: 15205206.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    262. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54. PMID: 15217937.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    263. Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EE. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70. PMID: 15161690.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    264. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15; 22(6):1025-33. PMID: 15020604.
      Citations: 167     Fields:    Translation:HumansCTClinical Trials
    265. Yang XJ, Sugimura J, Tretiakova MS, Furge K, Zagaja G, Sokoloff M, Pins M, Bergan R, Grignon DJ, Stadler WM, Vogelzang NJ, Teh BT. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer. 2004 Mar 01; 100(5):976-85. PMID: 14983493.
      Citations: 13     Fields:    Translation:Humans
    266. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 01; 22(5):909-18. PMID: 14990647.
      Citations: 257     Fields:    Translation:HumansCTClinical Trials
    267. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004 Jan 01; 22(1):115-9. PMID: 14701773.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    268. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71. PMID: 14692025.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    269. Stadler W. Developing drugs that do not cause tumor regression. Clin Adv Hematol Oncol. 2003 Nov; 1(11):654-5. PMID: 16258462.
      Citations:    Fields:    Translation:Humans
    270. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM, Vogelzang NJ. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5. PMID: 14501711.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    271. Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, Dorner AJ, Slonim DK, Trepicchio WL, Burczynski ME. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 2003 Sep 15; 63(18):6069-75. PMID: 14522937.
      Citations: 62     Fields:    Translation:HumansCells
    272. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B Study 9663. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8. PMID: 12860943.
      Citations: 113     Fields:    Translation:HumansCellsCTClinical Trials
    273. Stadler W, Wilding G. Angiogenesis inhibitors in genitourinary cancers. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S41-7. PMID: 12850526.
      Citations: 2     Fields:    Translation:Humans
    274. Stadler WM, Lerner SP. Perioperative chemotherapy in locally advanced bladder cancer. Lancet. 2003 Jun 07; 361(9373):1922-3. PMID: 12801730.
      Citations: 2     Fields:    Translation:Humans
    275. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7. PMID: 12743152.
      Citations: 144     Fields:    Translation:HumansCTClinical Trials
    276. Winquist E, Vincent M, Stadler W. Acute bilateral abducens paralysis due to oxaliplatin. J Natl Cancer Inst. 2003 Mar 19; 95(6):488-9. PMID: 12644545.
      Citations: 1     Fields:    Translation:Humans
    277. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol. 2003 Mar; 169(3):1122-33. PMID: 12576866.
      Citations: 59     Fields:    Translation:HumansAnimalsCells
    278. George CM, Stadler WM. The role of systemic chemotherapy in the treatment of kidney cancer. Cancer Treat Res. 2003; 116:173-82. PMID: 14650832.
      Citations: 3     Fields:    Translation:Humans
    279. Rosner GL, Stadler W, Ratain MJ, Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84. PMID: 12431972.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    280. Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch DW, Newlin R, Stadler W, Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch DW, Newlin R, Stadler W. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med. 2002 Nov; 113(7):603-6. PMID: 12459408.
      Citations: 15     Fields:    Translation:Humans
    281. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM, Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002 Oct 15; 95(8):1629-36. PMID: 12365009.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    282. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75. PMID: 12177096.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    283. Park DK, Ryan CW, Dolan ME, Vogelzang NJ, Stadler WM. A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol. 2002 Aug; 50(2):160-2. PMID: 12172983.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    284. Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol. 2002 Jul-Aug; 7(4):153-7. PMID: 12474531.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    285. Ryan CW, Vogelzang NJ, Stadler WM. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer. 2002 May 15; 94(10):2602-9. PMID: 12173327.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    286. Stadler W. New trial designs to assess antitumor and antiproliferative agents in prostate cancer. Invest New Drugs. 2002 May; 20(2):201-8. PMID: 12099580.
      Citations: 1     Fields:    Translation:Humans
    287. Rini BI, Paintal A, Vogelzang NJ, Gajewski TF, Stadler WM. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 2002 May-Jun; 25(3):269-77. PMID: 12000869.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    288. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ, Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002 Apr 15; 20(8):2017-24. PMID: 11956260.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    289. Stadler WM. Gemcitabine doublets in advanced urothelial cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 3):15-9. PMID: 11894003.
      Citations: 2     Fields:    Translation:Humans
    290. George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, Stadler WM. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol. 2002 Jan; 13(1):116-20. PMID: 11863091.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    291. Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology. 2001 Dec; 58(6):1016-20. PMID: 11744479.
      Citations: 2     Fields:    Translation:Humans
    292. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76. PMID: 11745236.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    293. Ryan CW, Stadler WM, Vogelzang NJ, Ryan CW, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 15):56-61. PMID: 11685730.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    294. Ratain MJ, Stadler WM, Ratain MJ, Stadler WM. Clinical trial designs for cytostatic agents. J Clin Oncol. 2001 Jun 15; 19(12):3154-5. PMID: 11408513.
      Citations: 4     Fields:    Translation:Humans
    295. Stadler WM, Steinberg G, Yang X, Hagos F, Turner C, Olopade OI. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res. 2001 Jun; 7(6):1676-82. PMID: 11410506.
      Citations: 6     Fields:    Translation:HumansCells
    296. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20. PMID: 11350886.
      Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
    297. Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA, Chekmareva MA, Ichikawa Y, Sokoloff MH, Zhan P, Karrison T, Lin A, Stadler WM, Ichikawa T, Rubin MA, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 2001 Apr 01; 61(7):2833-7. PMID: 11306453.
      Citations: 33     Fields:    Translation:HumansCells
    298. Cohen EE, Stadler WM. Treatment of metastatic urothelial cancer in the post-MVAC era. World J Urol. 2001 Apr; 19(2):126-32. PMID: 11374315.
      Citations:    Fields:    Translation:Humans
    299. Rini BI, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol. 2001 Apr; 165(4):1208-9. PMID: 11257677.
      Citations: 1     Fields:    Translation:Humans
    300. Vogelzang NJ, Aklilu M, Stadler WM, Dumas MC, Mikulski SM. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs. 2001; 19(3):255-60. PMID: 11561684.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    301. Chien M, Rinker-Schaeffer C, Stadler WM. A G2/M growth arrest response to low-dose intermittent H2O2 in normal uroepithelial cells. Int J Oncol. 2000 Sep; 17(3):425-32. PMID: 10938379.
      Citations: 6     Fields:    Translation:HumansCells
    302. Innocenti F, Stadler WM, Iyer L, Vokes EE, Ratain MJ, Ramírez J. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5. PMID: 10999721.
      Citations: 13     Fields:    Translation:Humans
    303. Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM, Getzenberg RH. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res. 2000 Jul; 6(7):2618-25. PMID: 10914702.
      Citations: 31     Fields:    Translation:Humans
    304. Rini BI, Vogelzang NJ, Dumas MC, Wade JL, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000 Jun; 18(12):2419-26. PMID: 10856102.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    305. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000 May; 18(9):1921-7. PMID: 10784633.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    306. Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer. 2000 Mar 15; 88(6):1317-24. PMID: 10717612.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    307. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs. 2000 Feb; 18(1):7-16. PMID: 10830137.
      Citations: 10     Fields:    Translation:Humans
    308. Stadler W. Renal cancer immunotherapy: a ray of hope or regression to the mean? Cancer Invest. 2000; 18(5):490-1. PMID: 10834033.
      Citations: 1     Fields:    Translation:Humans
    309. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol. 2000 Jan; 18(2):371-5. PMID: 10637252.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    310. Goh BC, Fleming GF, Janisch L, Vogelzang NJ, Stadler WM, Ratain MJ. Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000; 45(6):489-94. PMID: 10854137.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    311. Tennant TR, Rinker-Schaeffer CW, Stadler WM. Angiogenesis inhibitors. Curr Oncol Rep. 2000 Jan; 2(1):11-6. PMID: 11122819.
      Citations:    Fields:    Translation:HumansCells
    312. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 1999 Nov 01; 59(21):5483-7. PMID: 10554023.
      Citations: 52     Fields:    Translation:HumansAnimalsCells
    313. Beck TP, Kirsh EJ, Chmura SJ, Kovar DA, Chung T, Rinker-Schaeffer CW, Stadler WM. In vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer. Urology. 1999 Sep; 54(3):573-7. PMID: 10475376.
      Citations:    Fields:    Translation:HumansCells
    314. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol. 1999 Aug; 17(8):2541-5. PMID: 10561320.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    315. Vogelzang NJ, Stadler WM. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology. 1999 Feb; 53(2):243-50. PMID: 9933034.
      Citations:    Fields:    Translation:Humans
    316. Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C, Stadler WM. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol. 1999; 44(1):81-7. PMID: 10367753.
      Citations: 6     Fields:    Translation:HumansCells
    317. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet. 1998 Nov 21; 352(9141):1691-6. PMID: 9853456.
      Citations: 51     Fields:    Translation:Humans
    318. Chekmareva MA, Kadkhodaian MM, Hollowell CM, Kim H, Yoshida BA, Luu HH, Stadler WM, Rinker-Schaeffer CW. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases. Cancer Res. 1998 Nov 01; 58(21):4963-9. PMID: 9810006.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    319. Dubauskas Z, Beck TP, Chmura SJ, Kovar DA, Kadkhodaian MM, Shrivastav M, Chung T, Stadler WM, Rinker-Schaeffer CW. Activated calphostin C cytotoxicity is independent of p53 status and in vivo metastatic potential. Clin Cancer Res. 1998 Oct; 4(10):2391-8. PMID: 9796970.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    320. Stadler WM, Vogelzang NJ. Cytokine therapy in metastatic renal cancer. N Engl J Med. 1998 Sep 17; 339(12):849; author reply 850-1. PMID: 9750082.
      Citations:    Fields:    Translation:Humans
    321. Daugherty CK, Ratain MJ, Minami H, Banik DM, Vogelzang NJ, Stadler WM, Siegler M. Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12. PMID: 9667244.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    322. Fagbemi SO, Stadler WM. [New chemotherapy regimens for advanced bladder cancer]. Actas Urol Esp. 1998 Jun; 22(6):548-9. PMID: 9734137.
      Citations:    Fields:    Translation:Humans
    323. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol. 1998 May; 16(5):1820-5. PMID: 9586896.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    324. Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34. PMID: 9563886.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    325. Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial. Cancer. 1998 Apr 01; 82(7):1352-8. PMID: 9529028.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    326. Kirsh EJ, Baunoch DA, Stadler WM. Expression of bcl-2 and bcl-X in bladder cancer. J Urol. 1998 Apr; 159(4):1348-53. PMID: 9507882.
      Citations: 15     Fields:    Translation:Humans
    327. Fagbemi SO, Stadler WM. New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol. 1998 Feb; 16(1):23-9. PMID: 9508079.
      Citations:    Fields:    Translation:Humans
    328. Yeager TR, DeVries S, Jarrard DF, Kao C, Nakada SY, Moon TD, Bruskewitz R, Stadler WM, Meisner LF, Gilchrist KW, Newton MA, Waldman FM, Reznikoff CA. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev. 1998 Jan 15; 12(2):163-74. PMID: 9436977; PMCID: PMC316442.
      Citations: 25     Fields:    Translation:HumansCells
    329. Yoshida BA, Chekmareva MA, Wharam JF, Kadkhodaian M, Stadler WM, Boyer A, Watabe K, Nelson JB, Rinker-Schaeffer CW. Prostate cancer metastasis-suppressor genes: a current perspective. In Vivo. 1998 Jan-Feb; 12(1):49-58. PMID: 9575426.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    330. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997 Nov; 15(11):3394-8. PMID: 9363871.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    331. Reeder JE, Morreale JF, O'Connell MJ, Stadler WM, Olopade OF, Messing EM, Wheeless LL. Loss of the CDKN2A/p16 locus detected in bladder irrigation specimens by fluorescence in situ hybridization. J Urol. 1997 Nov; 158(5):1717-21. PMID: 9334586.
      Citations: 1     Fields:    Translation:Humans
    332. Stadler WM, Kuzel TM, Raghavan D, Levine E, Vogelzang NJ, Roth B, Dorr FA. Metastatic bladder cancer: advances in treatment. Eur J Cancer. 1997 Jan; 33 Suppl 1:S23-6. PMID: 9166096.
      Citations: 3     Fields:    Translation:Humans
    333. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 1996 Oct; 156(4):1280-5. PMID: 8808854.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    334. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996 Aug; 156(2 Pt 1):363-7. PMID: 8683680.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    335. Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 1996 Jul 01; 56(13):2886-90. PMID: 8674033.
      Citations: 39     Fields:    Translation:HumansCells
    336. Shulman KL, Stadler WM, Vogelzang NJ. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. Urology. 1996 Feb; 47(2):194-7. PMID: 8607232.
      Citations: 1     Fields:    Translation:Humans
    337. Stadler WM, Olopade OI. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res. 1996; 24(4):239-44. PMID: 8873383.
      Citations: 15     Fields:    Translation:HumansCells
    338. Stadler WM, Rybak ME, Vogelzang NJ. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer. 1995 Nov 01; 76(9):1629-33. PMID: 8635068.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    339. Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa R, Dreyling MH, Gursky S, Stadler WM, Le Beau MM, Bohlander SK. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci U S A. 1995 Jul 03; 92(14):6489-93. PMID: 7604019; PMCID: PMC41543.
      Citations: 19     Fields:    Translation:HumansCells
    340. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 1995 Feb 01; 55(3):493-7. PMID: 7834615.
      Citations: 29     Fields:    Translation:HumansCells
    341. Stadler WM, Vogelzang NJ. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol. 1995 Feb; 22(1):67-73. PMID: 7855621.
      Citations: 4     Fields:    Translation:HumansAnimals
    342. Stadler WM, Sherman J, Bohlander SK, Roulston D, Dreyling M, Rukstalis D, Olopade OI. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res. 1994 Apr 15; 54(8):2060-3. PMID: 7513608.
      Citations: 19     Fields:    Translation:HumansCells
    343. Vogelzang NJ, Stadler W, Rukstalis D. The cure of bladder cancer: the need for multidisciplinary efforts. J Urol. 1994 Mar; 151(3):605-6. PMID: 8308968.
      Citations:    Fields:    Translation:Humans
    344. Stadler W. Molecular events in the initiation and progression of bladder-cancer (review). Int J Oncol. 1993 Oct; 3(4):549-57. PMID: 21573399.
      Citations: 1     Fields:    
    345. Stadler W, Vogelzang NJ. Human renal cancer carcinogenesis: a review of recent advances. Ann Oncol. 1993 Jun; 4(6):451-62. PMID: 8394735.
      Citations: 6     Fields:    Translation:HumansAnimals
    346. Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst. 1992 Dec 02; 84(23):1835-6. PMID: 1433373.
      Citations: 9     Fields:    Translation:Humans
    347. Stadler WM, Vogelzang NJ, Vokes EE, Charette J, Whitman G. Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer. Cancer Chemother Pharmacol. 1992; 31(3):213-6. PMID: 1464158.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    348. Lipsky H, Stadler W. [Changes in the treatment of urogenital tuberculosis]. Wien Klin Wochenschr. 1988 Sep 09; 100(17):573-6. PMID: 3188530.
      Citations:    Fields:    Translation:Humans
    Stadler's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (808)
    Explore
    _
    Co-Authors (100)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _